Induction of the 'ASIA' syndrome in NZB/NZWF1 mice after injection of complete Freund's adjuvant (CFA)

Lupus

Volumn 21, Issue 2, 2012, Pages 203-209

  Bassi, N ^a   Luisetto, R ^a   Prete, D Del ^a   Ghirardello, A ^a   Ceol, M ^a   Rizzo, S ^a   Iaccarino, L ^a   Gatto, M ^a   Valente, M L ^a   Punzi, L ^a   Doria, A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

adjuvants; ASIA syndrome; NZB NZWF1 mice; systemic lupus erythematosus; vaccines

Indexed keywords

DOUBLE STRANDED DNA ANTIBODY; FREUND ADJUVANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE AUTOINFLAMMATORY SYNDROME INDUCED BY ADJUVANT; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; EXPERIMENTAL MODEL; GLOMERULONEPHRITIS; HISTOPATHOLOGY; INJECTION; LYMPHOID HYPERPLASIA; MOUSE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL RATE; VASCULITIS;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DNA; FEMALE; FREUND'S ADJUVANT; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED NZB; SURVIVAL RATE; SYNDROME;

EID: 84855810026     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203311429553     Document Type: Article

References (52)

1. Shoenfeld Y, Agmon-Levin N. 'ASIA'-Autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011 ; 36: 4-8
2. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus. 2009 ; 18: 1217-1225
3. Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008 ; 9: 847-856
4. Mackay IR. Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev. 2010 ; 9: A251 - A258
5. Schijns VEJC. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol. 2000 ; 12: 456-463
6. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine. 2010 ; 28s: C25 - C36
7. Rose NR. Autoimmunity, infection and adjuvants. Lupus. 2010 ; 19: 354-358
8. Warchoł T, Lianeri M, Olesińska M, Jagodziński PP. Interleukin-18 promoter polymorphisms in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2011 ; 29: 310-313
9. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol. 1997 ; 27: 2340-2344 (Pubitemid 27404319)
10. Zorro S, Arias M, Riaño F, et al. Response to ODN-CpG by B Cells from patients with systemic lupus erythematosus correlates with disease activity. Lupus. 2009 ; 18: 718-726
11. Jiang C, Zhao ML, Scearce RM, Diaz M. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis. Arthritis Rheum. 2011 ; 63: 1086-1096
12. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008 ; 453: 1122-1126 (Pubitemid 351871731)
13. Tokunaga T, Yano O, Kuramoto E, et al. Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells. Microbiol Immunol. 1992 ; 36: 55-66
14. Doria A, Zen M, Canova M, et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev. 2010 ; 10: 55-60
15. Pisetsky DS, Vrabie IA. Antibodies to DNA: infections or genetics?. Lupus. 2009 ; 18: 1176-1180
16. Zandman-Goddard G, Peeva E, Shoenfeld Y. Gender influences SLE-immune cells, genetics, experimental models and lupus patients. Clin Exp Rheumatol. 2010 ; 28: 297-299
17. Ghirardello A, Doria A, Zampieri S, et al. Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J Autoimmun. 2004 ; 22: 235-240 (Pubitemid 38369184)
18. Festing MFW. Inbred strains of mice. Mouse Genome. 1997 ; 95: 519-686
19. Gomez-Martin D, Diaz-Zamudio M, Crispin JC, Alcocer-Varela J. Interleukin 2 and systemic lupus erythematosus: beyond the transcriptional regulatory net abnormalities. Autoimmun Rev. 2009 ; 9: 34-39
20. Glück T, Muller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis. 2008 ; 46: 1459-1465 (Pubitemid 351589953)
21. Doria A, Canova M, Tonon M, et al. Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev. 2008 ; 8: 24-28
22. Doria A, Zampieri S, Sarzi-Puttini P. Exploring the complex relationships between infections and autoimmunity. Autoimmun Rev. 2008 ; 8: 89-91
23. Cooke A, Ferraccioli G, Herrmann M, et al. Induction and protection of autoimmune rheumatic diseases. The role of infections. Clin Exp Rheumatol. 2008 ; 26: S1 - S7
24. Girschick HJ, Guilherme L, Inman RD, et al. Bacterial triggers and rheumatic diseases. Clin Exp Rheumatol. 2008 ; 26: S12 - S17
25. Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence?. Lancet. 2003 ; 362: 1659-1666 (Pubitemid 37443537)
26. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine. 2005 ; 23: 3876-3886 (Pubitemid 40726180)
27. Pavlovic M, Kats A, Cavallo M, Shoenfeld Y. Clinical and molecular evidence for association of SLE with parvovirus B19. Lupus. 2010 ; 19: 783-792
28. Pender MP. Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. Autoimmun Rev. 2009 ; 8: 563-568
29. Orbach H, Agmon-Levin N, Zandman-Goddard G. Vaccines and autoimmune diseases of the adult. Discov Med. 2010 ; 9: 90-97
30. Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity. 2005 ; 38: 295-301 (Pubitemid 40974959)
31. Abu-Shakra M. Safety of vaccination of patients with systemic lupus erythematosus. Lupus. 2009 ; 18: 1205-1208
32. Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol. 2009 ; 5: 648-652
33. Di Benedetto G, Pierangeli M, Scalise A, Bertani A. Paraffin oil injection in the body: an obsolete and destructive procedure. Ann Plast Sur. 2002 ; 49: 391-396
34. Anderson PN, Potter M. Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature. 1969 ; 222: 994-995
35. Carlson BC, Jansson AM, Larsson A, Buch A, Lorentzen JC. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am J Pathol. 2000 ; 156: 2057-2065 (Pubitemid 30641773)
36. Satoh M, Reeves WH. Induction on lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med. 1994 ; 180: 2341-2346 (Pubitemid 24351616)
37. Kuroda Y, Nacionales DC, Akaogi J, Reeves WH, Satoh M. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother. 2004 ; 58: 325-337 (Pubitemid 38759732)
38. Orbach H, Tanay A. Vaccines as trigger for myopathies. Lupus. 2009 ; 18: 1213-1216
39. Mikaeloff Y, Caridade G, Suissa S, Tardieu M. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology. 2009 ; 72: 873-880
40. Spiera RF, Gibofsky A, Spiera H. Silicone gel filled breast implants and connective tissue disease: an overview. J Rheumatol. 1994 ; 21: 239-245 (Pubitemid 24078833)
41. Gherardi RK. Lessons from macrophagic myofasciitis: towards definition of a vaccine adjuvant-related syndrome. Rev Neurolog. 2003 ; 159: 162-164 (Pubitemid 36292557)
42. Asa PB, Wilson RB, Garry RF. Antibodies to squalene in recipients of anthrax vaccine. Exp Mol Pathol. 2002 ; 73: 19-27 (Pubitemid 34775454)
43. Lippi G, Targher G, Franchini M. Vaccination, squalene and anti-squalene antibodies: facts or fiction?. Eur J Intern Med. 2010 ; 21: 70-73
44. Gronseth GS. Gulf war syndrome: a toxic exposure? A systematic review. Neurol Clin. 2005 ; 23: 523-540 (Pubitemid 40332612)
45. Asa PB, Cao Y, Garry RF. Antibodies to squalene in Gulf War syndrome. Exp Mol Pathol. 2000 ; 68: 55-64 (Pubitemid 30082846)
46. Kluger N, Cohen P, Fallet-Bianco C, Guillevin L. Mycobacterium chelonae infection under adalimumab therapy for spondylarthritis. Clin Exp Rheumatol. 2010 ; 28: 101-102
47. Yazisiz V, Erbasan F, Inan D, et al. Bone marrow infection caused by Mycobacterium avium complex in a patient with systemic lupus erythematosus. Lupus. 2010 ; 19: 323-326
48. Doria A, Sarzi-Puttini P, Shoenfeld Y. Infections, rheumatism and autoimmunity: the conflicting relationship between humans and their environment. Autoimmun Rev. 2008 ; 8: 1-4
49. Sarzi-Puttini P, Atzeni F, Iaccarino L, Doria A. Environment and systemic lupus erythematosus: an overview. Autoimmunity. 2005 ; 38: 465-472 (Pubitemid 43101780)
50. Doria A, Iaccarino L, Ghirardello A, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006 ; 119: 1497-1499
51. Rinaldi S, Doria A, Salaffi F, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age. Rheumatology. 2004 ; 43: 1574-1579 (Pubitemid 39642586)
52. Doria A, Rinaldi S, Ermani M, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological, and psychological determinants. Rheumatology. 2004 ; 43: 1580-1586 (Pubitemid 39642587)